January 11, 2017 - By Linda Rogers · 0 Comments
Becton Dickinson & Co (NYSE:BDX) institutional sentiment increased to 0.9 in Q3 2016. Its up 0.01, from 0.89 in 2016Q2. The ratio increased, as 357 investment managers increased or opened new equity positions, while 395 sold and reduced equity positions in Becton Dickinson & Co. The investment managers in our partner’s database reported: 170.25 million shares, down from 178.24 million shares in 2016Q2. Also, the number of investment managers holding Becton Dickinson & Co in their top 10 equity positions decreased from 51 to 48 for a decrease of 3. Sold All: 61 Reduced: 334 Increased: 278 New Position: 79.
Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The company has a market cap of $37.44 billion. The Firm operates through two divisions: BD Medical and BD Life Sciences. It has a 38.58 P/E ratio. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
About 1.00 million shares traded hands. Becton Dickinson and Co (NYSE:BDX) has risen 1.38% since June 7, 2016 and is uptrending. It has underperformed by 6.05% the S&P500.
Analysts await Becton Dickinson and Co (NYSE:BDX) to report earnings on February, 1. They expect $2.12 EPS, up 8.16% or $0.16 from last year’s $1.96 per share. BDX’s profit will be $457.61 million for 20.45 P/E if the $2.12 EPS becomes a reality. After $2.12 actual EPS reported by Becton Dickinson and Co for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BD’s operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.”
Caledonia Investments Plc holds 8.47% of its portfolio in Becton Dickinson and Co for 135,800 shares. Jensen Investment Management Inc owns 2.26 million shares or 6.06% of their US portfolio. Moreover, Troy Asset Management Ltd has 5.63% invested in the company for 585,900 shares. The France-based Comgest Global Investors S.A.S. has invested 5.18% in the stock. Fundsmith Llp, a United Kingdom-based fund reported 2.06 million shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 5 insider sales for $9.83 million net activity.
Ratings analysis reveals 36% of Becton Dickinson’s analysts are positive. Out of 11 Wall Street analysts rating Becton Dickinson, 4 give it “Buy”, 1 “Sell” rating, while 6 recommend “Hold”. The lowest target is $146 while the high is $195. The stock’s average target of $166.67 is -3.91% below today’s ($173.45) share price. BDX was included in 18 notes of analysts from August 7, 2015. The stock of Becton Dickinson and Co (NYSE:BDX) has “Neutral” rating given on Thursday, February 4 by Citigroup. The rating was maintained by RBC Capital Markets with “Sector Perform” on Thursday, February 4. The firm earned “Sell” rating on Friday, September 23 by Citigroup. RBC Capital Markets maintained the shares of BDX in a report on Friday, August 7 with “Sector Perform” rating. The rating was downgraded by Morgan Stanley on Monday, January 4 to “Equal-Weight”. The firm earned “Neutral” rating on Tuesday, January 3 by JP Morgan. The stock has “Buy” rating given by Deutsche Bank on Thursday, February 11. On Thursday, January 5 the stock rating was downgraded by Raymond James to “Outperform”. The stock of Becton Dickinson and Co (NYSE:BDX) earned “Neutral” rating by Citigroup on Thursday, November 12. The firm earned “Hold” rating on Monday, August 10 by Deutsche Bank.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology firm engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Firm operates through two divisions: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Firm caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A.
More recent Becton Dickinson and Co (NYSE:BDX) news were published by: Reuters.com which released: “BRIEF-Becton Dickinson And Co launches BD Neopak 2.25 ml prefillable glass…” on December 15, 2016. Also Seekingalpha.com published the news titled: “Becton, Dickinson: Does This Dividend Aristocrat Measure Up To Its Peers?” on January 08, 2017. Nasdaq.com‘s news article titled: “Centre Asset Management, LLC Buys Adobe Systems Inc, Coach Inc, Becton …” with publication date: January 10, 2017 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers